Search
10/02/2025
Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.
Rioja, P, Passarella, C, Angel, M, Valderrama, W, Bosma, F, Anguera, G, Gomez, V, Ruiz-Granados, A, Plata, D, Laguado, MIZ, Orta-Ruiz, A, Gandur-Quiroga, MN, Bourlon, MT, Grande, E, Manneh, R, Molina-Cerrillo, J, Maroto-Rey, P, Sade, JP, Castellano, D. Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.502. PMID:. IF:41.900(Q1/1D).
10/02/2025
Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study.
Lista, AGD, Romero-Laorden, N, Gajate, P, Orta-Ruiz, A, Jiménez, JGD, Miranda, MJ, Estévez, SV, Molins, C, Pernaut, C, Cordero, MG, Fernández, O, Sánchez, JG, Maeso, IG, Blazquez, PR, Reig, O, Maroto-Rey, P, Martín, A, Ramirez, I, Puente, J. Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.720. PMID:. IF:41.900(Q1/1D).
09/02/2025
Megaprosthesis Infection by Bacteroides fragilis in a Patient With Ewing's Sarcoma: A Case Report and Literature Review
Martínez-Ysasis, Y, Simonetti, AF, Navarro, F. Megaprosthesis Infection by Bacteroides fragilis in a Patient With Ewing's Sarcoma: A Case Report and Literature Review. Clinical Case Reports. 2025; 13(2)DOI:10.1002/ccr3.70185. PMID:39931721. IF:(Q/D).
07/02/2025
Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectiveness
Cardoner, N, Gutiérrez-Rojas, L, Saiz, P, Lahera, G, alvarez-Mon, MA, Ortega, PA, Pérez-Páramo, M. Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectiveness. Frontiers in Pharmacology. 2025; 16DOI:10.3389/fphar.2025.1483770. PMID:39989902. IF:4.800(Q1/2D).